CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Impact · against what's priced in

Cytokinetics faces potential regulatory delays for aficamten due to allegations of missing REMS requirements and misleading NDA timelines, which introduces significant downside risk to its 2025 approval expectations. BZAI and DVLT are also facing securities litigation, though the impact is primarily legal overhang.

CYTK−0.60

No priced-in read yet